STOCK TITAN
  1. Home
  2. Sec-filings
  3. TRAW
  4. [Form 4] Traws Pharma, Inc. Insider Trading Activity

Traws Pharma (TRAW) awards 14,150 stock options to director Jack E. Stover

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Traws Pharma, Inc. director Jack E. Stover received a grant of stock options for 14,150 shares of common stock on July 9, 2026. The options have a $0.68 exercise price, were awarded under the 2021 Incentive Compensation Plan, and were granted at $0.00 per option as compensation. They vest 100% on the first anniversary of the grant date and expire on July 9, 2036. Following this award, Stover directly holds options covering 14,150 shares.

Positive

  • None.

Negative

  • None.
Insider STOVER JACK E
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 14,150 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 14,150 shares (Direct)
Footnotes (1)
  1. [object Object]
Stock options granted 14,150 options Stock Option (right to buy) award to Jack E. Stover on July 9, 2026
Exercise price $0.68 per share Conversion or exercise price of the stock options
Grant price per option $0.00 per option Compensation grant, not an open-market purchase or sale
Vesting schedule 100% after 1 year Options vest 100% on the first anniversary of the grant date
Expiration date July 9, 2036 Expiration of stock options granted to Jack E. Stover
Post-award options held 14,150 options Total derivative securities following the reported transaction
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
2021 Incentive Compensation Plan financial
"under the Issuer's 2021 Incentive Compensation Plan"
vest 100% on the first anniversary financial
"The stock options under this award will vest 100% on the first anniversary"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What did Traws Pharma (TRAW) report for director Jack E. Stover in this Form 4?
Traws Pharma reported that director Jack E. Stover received 14,150 stock options on July 9, 2026. These options are compensation, not open-market purchases, and give him the right to buy common shares at a fixed $0.68 exercise price in the future.

How many stock options did Jack E. Stover receive from Traws Pharma (TRAW)?
Jack E. Stover received 14,150 stock options from Traws Pharma. Each option relates to one share of common stock, so the award covers rights to purchase 14,150 shares if he chooses to exercise them under the plan terms.

What is the exercise price of Jack E. Stover’s Traws Pharma (TRAW) options?
The granted stock options have an exercise price of $0.68 per share. This means Stover can later buy up to 14,150 Traws Pharma common shares at $0.68 each, regardless of the market price at the time of exercise.

When do Jack E. Stover’s Traws Pharma (TRAW) stock options vest?
The stock options vest 100% on the first anniversary of the July 9, 2026 grant date. Stover must remain eligible through that one-year period to receive full vesting, after which all 14,150 options become exercisable at the stated price.

When do Jack E. Stover’s Traws Pharma (TRAW) options expire?
The stock options granted to Jack E. Stover expire on July 9, 2036. After this expiration date, any unexercised portion of the 14,150 options will lapse, and he will no longer have the right to buy shares under this award.

Under which plan were Jack E. Stover’s Traws Pharma (TRAW) options granted?
The options were granted under Traws Pharma’s 2021 Incentive Compensation Plan, as amended and/or restated. The filing notes they were awarded by the compensation committee of independent directors as part of Stover’s equity-based compensation.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
STOVER JACK E
(Last)(First)(Middle)
C/O TRAWS PHARMA, INC
12 PENNS TRAIL
(Street)
NEWTOWN PENNSYLVANIA 18940
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$0.6807/09/2026A14,15007/09/2027(1)07/09/2036Common Stock14,150$014,150D
Explanation of Responses:
1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
/s/ Jack E. Stover07/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR